Related Experiment Video
Updated: Jul 5, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
Platelet aggregation is not enhanced in patients with prediabetes
Teoman Dogru1, Halil Genc, Ilker Tasci
1Department of Internal Medicine,Etlik, Ankara, Turkey. teomandogru@yahoo.com
Upsala Journal of Medical Sciences
|May 17, 2008
Summary
Prediabetes, a precursor to type 2 diabetes, shows higher fibrinogen levels but not altered platelet aggregation compared to healthy individuals. This suggests platelet aggregation may not drive the prothrombotic state in prediabetes.
Area of Science:
- Endocrinology
- Hematology
- Cardiovascular Medicine
Background:
- Prediabetes, encompassing impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), is a significant risk factor for type 2 diabetes (T2DM), cardiovascular disease, and mortality.
- The prothrombotic state in prediabetes is not fully understood, particularly concerning platelet function and fibrinogen levels in individuals without confounding factors like hypertension or obesity.
Purpose of the Study:
- To investigate platelet aggregation and fibrinogen levels in prediabetic subjects compared to healthy controls.
- To determine if altered platelet aggregation contributes to the prothrombotic state in prediabetes, independent of other risk factors.
Main Methods:
- A case-control study involving 39 prediabetic subjects (24 IFG, 15 IGT) and 36 matched healthy controls.
- Measurements included platelet aggregation (induced by collagen, epinephrine, ADP), plasma fibrinogen, hsCRP, HOMA-IR, and HOMA-beta index.
Main Results:
- Fibrinogen levels were significantly higher in prediabetic subjects compared to controls (p=0.006).
- Platelet aggregation induced by collagen, epinephrine, or ADP did not differ significantly between the groups (p=0.93, p=0.90, p=0.29, respectively).
- Levels of hsCRP, HOMA-IR, and HOMA-beta index were comparable between prediabetics and controls.
Conclusions:
- Elevated plasma fibrinogen in prediabetes does not correlate with increased platelet aggregation.
- Platelet aggregation may not be a primary mechanism contributing to the prothrombotic state observed in prediabetes.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...